We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Clinical Efficacy and Safety of Iguratimod in RA and Early RA Patients for 6 Months Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03855007
Recruitment Status : Active, not recruiting
First Posted : February 26, 2019
Last Update Posted : September 22, 2022
Sponsor:
Information provided by (Responsible Party):
Qiang Shu, Qilu Hospital of Shandong University

Brief Summary:
This study is designed to observed prospectively the efficacy and safety of 6 months treatment of iguratimod alone, or with methotrexate (MTX), hydroxychloroquine (HCQ) and prednisone step by step on Chinese rheumatoid arthritis (RA) and early rheumatoid arthritis (ERA) patients who were naïve or shown insufficiency response or intolerance to DMARDs. If volunteered, patients who completed the 6-month study can continue to follow our plans for 24 months.

Condition or disease Intervention/treatment Phase
Arthritis, Rheumatoid Drug: Iguratimod Drug: MTX Drug: HCQ Drug: Pred Phase 4

Detailed Description:
This study will enroll 200 cases of rheumatoid arthritis (RA) and early rheumatoid arthritis (ERA) patients in China, who are naïve or shown insufficiency response or intolerance to DMARDs. The participants plan to be treated with iguratimod alone, or along with methotrexate (MTX)/ hydroxychloroquine (HCQ) / prednisone (Pred) step by step for 6 months if participants are in medium or high disease activity (DAS28≥3.2). Participants can choose to continue the study up to 24 months.The efficacy and safety of 6 months and 24 months Iguratimod treatment in RA and ERA patients will be evaluated with DAS28-ESR and other disease activity indices.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description:

Drug: Iguratimod(T-614),25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.

Drug: Methotrexate (MTX),7.5mg to 15mg, po, once per week (Qw) prescribed if needed and adjusted due to patient response or unacceptable toxicity develops.

Drug: Hydroxychloroquine (HCQ),200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.

Drug: Prednisone (Pred): 5-15mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response

Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prospective Clinical Study to Observe the Efficacy and Safety of Iguratimod in Rheumatoid Arthritis and Early Rheumatoid Arthritis Patients for 6 Months Treatment in China
Actual Study Start Date : January 1, 2016
Estimated Primary Completion Date : December 31, 2025
Estimated Study Completion Date : December 31, 2025

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Iguratimod
The participants plan to be treated with iguratimod alone, or along with methotrexate (MTX), hydroxychloroquine (HCQ) , prednisone (Pred) step by step
Drug: Iguratimod
Iguratimod tablet,25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
Other Name: T-614

Drug: MTX
MTX,7.5mg to 15mg, po, once per week (Qw) prescribed if needed and adjusted due to patient response or unacceptable toxicity develops.
Other Name: methotrexate

Drug: HCQ
HCQ,200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.
Other Name: Hydroxychloroquine

Drug: Pred
Pred, 5-15mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response
Other Name: Prednisone




Primary Outcome Measures :
  1. The percentage of patients who achieve clinical remission at week 24 using European League Against Rheumatism (EULAR) response criteria DAS28 [ Time Frame: week 24 ]
    The percentage of patients whose Disease Activity Score in 28 Joints (DAS28) achieve remission(DAS28-ESR≤ 2.6)and Low Disease Activity (DAS28-ESR ≤ 3.2). The DAS28 is a composite score derived from 4 of these measures,that is the count of tender joint count(TJC, 0-28)and swollen joint count(SJC, 0-28), measure erythrocyte sedimentation rate (ESR, mm/h) or C reactive protein (CRP, mg/L) and to make a patient assessment of disease activity i.e. 'global assessment of health' (GH) using a 100 mm visual analogue scale (VAS) with 0 = best, 100 = worst. DAS28 values were calculated as follows: DAS28- ESR = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 x GH. High disease activity: DAS28-ESR > 5.1; Moderate disease activity: 5.1≥ DAS28 > 3.2 to 5.1; Low disease activity (LDA) and Remission mean Clinical remission.


Secondary Outcome Measures :
  1. The percentage of patients who achieve clinical remission using DAS28-ESR at week 12 [ Time Frame: week 12 ]
    The percentage of patients whose DAS28 achieve remission(DAS28-ESR≤ 2.6)and Low Disease Activity (DAS28-ESR ≤ 3.2) at week 12.

  2. The percentage of patients who achieve clinical remission using DAS28-ESR at week 48 [ Time Frame: week 48 ]
    The percentage of patients whose DAS28 achieve remission(DAS28-ESR≤ 2.6)and Low Disease Activity (DAS28-ESR ≤ 3.2) at week 12.response states were classified as follows: good responders were patients with an improvement from baseline (△DAS28-ESR) of > 1.2 and a DAS28-ESR at week 12 ≤ 3.2. Moderate responders: △DAS28 > 1.2 and still DAS28 > 3.2 at week 12, or 1.2 ≥△DAS28 > 0.6 and DAS28 ≤ 5.1 at week 12. Nonresponders:△DAS28 ≤0.6 or DAS28 >5.1 at week 12. DAS28-defined remission was classified as a score of <2.6.

  3. The percentage of patients who achieve clinical remission using DAS28-ESR at week 96 [ Time Frame: week 96 ]
    The percentage of patients whose DAS28 achieve remission(DAS28-ESR≤ 2.6)and Low Disease Activity (DAS28-ESR ≤ 3.2) at week 12Nonresponders:△DAS28 ≤0.6,or DAS28 >5.1 at week 24. DAS28-defined remission was classified as a score of <2.6.

  4. Percentage of Disease Activity Score 28 (DAS28) -ESR Criteria Responders at week 12 [ Time Frame: week 12 ]
    △DAS28 indicates the decline of DAS28-ESR from the baseline to week 12. EULAR response states were classified as follows: good responders were patients with an improvement from baseline (△DAS28-ESR) of > 1.2 and a DAS28-ESR at week 12 ≤ 3.2. Moderate responders: △DAS28 > 1.2 and still DAS28 > 3.2 at week 12, or 1.2 ≥△DAS28 > 0.6 and DAS28 ≤ 5.1 at week 12. Nonresponders:△DAS28 ≤0.6 or DAS28 >5.1 at week 12. DAS28-defined remission was classified as a score of <2.6.

  5. Percentage of Disease Activity Score 28 (DAS28)-ESR Criteria Responders at week 24 [ Time Frame: week 24 ]
    EULAR response states were classified as follows: DAS28-ESR Good responders: △DAS28 > 1.2 and DAS28 ≤3.2 at week 24. Moderate responders:△DAS28 > 1.2 and still DAS28 > 3.2 at week 24; or 1.2 ≥△DAS28 > 0.6 and DAS28 ≤ 5.1 at week 24. Nonresponders:△DAS28 ≤0.6,or DAS28 >5.1 at week 24. DAS28-defined remission was classified as a score of <2.6.

  6. Percentage of Disease Activity Score 28 (DAS28)-ESR Criteria Responders at week 48 [ Time Frame: week 48 ]
    EULAR response states were classified as follows: DAS28-ESR Good responders: △DAS28 > 1.2 and DAS28 ≤3.2 at week 24. Moderate responders:△DAS28 > 1.2 and still DAS28 > 3.2 at week 24; or 1.2 ≥△DAS28 > 0.6 and DAS28 ≤ 5.1 at week 24. Nonresponders:△DAS28 ≤0.6,or DAS28 >5.1 at week 24. DAS28-defined remission was classified as a score of <2.6.

  7. Percentage of Disease Activity Score 28 (DAS28)-ESR Criteria Responders at week 96 [ Time Frame: week 96 ]
    EULAR response states were classified as follows: DAS28-ESR Good responders: △DAS28 > 1.2 and DAS28 ≤3.2 at week 24. Moderate responders:△DAS28 > 1.2 and still DAS28 > 3.2 at week 24; or 1.2 ≥△DAS28 > 0.6 and DAS28 ≤ 5.1 at week 24. Nonresponders:△DAS28 ≤0.6,or DAS28 >5.1 at week 24. DAS28-defined remission was classified as a score of <2.6.

  8. Percentage of participants achieving ACR/EULAR remission at week 12 [ Time Frame: week 12 ]
    If all of the following 4 parameters are fulfilled, it is defined as remission: TJC ≤ 1, SJC ≤ 1, CRP ≤ 1 mg/dL, Patient global assessment(PGA) ≤ 1 cm (on a visual analog scale ranging from 0-10 cm, with higher scores indicating severe disease).

  9. Percentage of participants achieving ACR/EULAR remission at week 24 [ Time Frame: week 24 ]
    If all of the following 4 parameters are fulfilled, it is defined as remission: TJC ≤ 1, SJC ≤ 1, CRP ≤ 1 mg/dL, Patient global assessment(PGA) ≤ 1 cm (on a visual analog scale ranging from 0-10 cm, with higher scores indicating severe disease).

  10. Percentage of participants achieving ACR/EULAR remission at week 48 [ Time Frame: week 48 ]
    If all of the following 4 parameters are fulfilled, it is defined as remission: TJC ≤ 1, SJC ≤ 1, CRP ≤ 1 mg/dL, Patient global assessment(PGA) ≤ 1 cm (on a visual analog scale ranging from 0-10 cm, with higher scores indicating severe disease).

  11. Percentage of participants achieving ACR/EULAR remission at week 96 [ Time Frame: week 96 ]
    If all of the following 4 parameters are fulfilled, it is defined as remission: TJC ≤ 1, SJC ≤ 1, CRP ≤ 1 mg/dL, Patient global assessment(PGA) ≤ 1 cm (on a visual analog scale ranging from 0-10 cm, with higher scores indicating severe disease).

  12. Percentage of American College of Rheumatology [ACR] 20 Criteria Responders every 3 months [ Time Frame: Up to week 96 ]
    Percentage of American College of Rheumatology [ACR] 20 Criteria Responders every 3 months

  13. Change from baseline Simplified Disease Activity Index (SDAI) [ Time Frame: Up to week 96 ]
    The SDAI is a composite score derived from these measures,that is the count of tender joint count(TJC, 0-28), swollen joint count(SJC, 0-28), C-reactive protein (CRP, mg/L), Patient global assessment(PGA)and physician global assessment(PHGA), each of the last two was assessed on a visual analog scale ranging from 0-10 cm, with higher scores indicating severe disease. SDAI score will be calculated with formula SDAI = TJC + SJC + PGA+PHGA+ CRP. SDAI score exceeding 26 is considered high disease activity; 11 <SDAI ≤26,moderate disease activity; 3.3 <SDAI ≤11, low disease activity; remission is SDAI score ≤ 3.3.

  14. Change from baseline Clinical Disease Activity Index (CDAI) [ Time Frame: Up to week 96 ]
    CDAI is a composite score derived from these measures,that is the count of tender joint count(TJC, 0-28), swollen joint count(SJC, 0-28), Patient global assessment(PGA)and physician global assessment(PHGA), each of the last two was CDAI score will be calculated with formula CDAI = TJC + SJC + PGA + PHGA. CDAI > 22 is considered high disease activity; 10 <CDAI ≤ 22, moderate disease activity; 2.8 <CDAI ≤10, low disease activity; remission is CDAI score ≤2.8.

  15. Change From Baseline in C-reactive Protein (CRP) [ Time Frame: Up to week 96 ]
    Change from Baseline in C-reactive Protein (CRP), a component index of ACR20 and SDAI, CRP will be measured with blood samples.

  16. Change From Baseline in Erythrocyte Sedimentation Rate (ESR) [ Time Frame: Up to week 96 ]
    Change from Baseline in ESR, that is a component index of ACR20, DAS28-ESR and SDAI, ESR will be measured with blood samples.

  17. Change from baseline Health Assessment Questionnaire Disability Index (HAQ-DI) [ Time Frame: Up to week 96 ]
    Change from Baseline in HAQ-DI, a participant assessed measure of health assessment, shaveing eight dimensions of functional activity: pruning, dressing, rising, eating, walking, personal hygiene, reach, grip, and other routine activities. Each item on a single scale has 4 degrees ranging from 0 (no functional difficulty) to 3 (unable to do), with higher scores indicating severe disease.

  18. Incidence of participant withdrawal [ Time Frame: Up to week 96 ]
    Percentage of participants who withdraw from this study.

  19. Number of participants with"adverse events (AEs)" [ Time Frame: Up to week 96 ]
    An AE is any untoward medical occurrence in a subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with"adverse events (AEs)"i.e. physical exam abnormalities,vital sign abnormalities,laboratory value abnormalities,symptom or disease (new or exacerbated) temporally associated with the use of a medicinal product.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   16 Years to 90 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria: -

  1. RA: Patients diagnosed based on 1987 ACR classification criteria for rheumatoid arthritis(RA);
  2. ERA: Subjects diagnosed by the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR); or by 2012 Chinese classification criteria of early rheumatoid arthritis (ERA), and not match the 1987 ACR criteria for RA.
  3. Age ≥16 years;
  4. Extra-articular manifestations (such as pulmonary fibrosis, proteinuria, leukopenia and peripheral neuropathy ) of RA patients are stable or no significant progress;
  5. Patients can be naïve to any DMARDs, or relapse due to DMARDs drug suspended;
  6. Patients have a history of using csDMARDs including csDMARDs(methotrexate,leflunomide, hydroxychloroquine, sulfasalazine, tacrolimus) , any biologic DMARDs(TNFi,tocilizumab or Tofacitinib),glucocorticoid (prednisone,methylprednisolone) or Chinese traditional Medicine(including tripterygium Glycosides, sinomenine)for 3 months, but couldn't achieve clinical remission or intolerance;

Exclusion Criteria:

  1. Patients with acute or chronic infections such as active bacterial, viral, fungal, tuberculosis infection or active hepatitis B;
  2. Platelet counts(PLT) <80 x 10^9 / L, or white blood cell (WBC) <3 x 10^9 / L;
  3. Propionate acid aminotransferase (ALT) or aspartate aminotransferase (AST) is two times higher than the upper limit of normal;
  4. Renal insufficiency: serum Cr ≥ 176 umol / L;
  5. Pregnant or nursing women (breastfeeding) ;
  6. Patients has a history of malignancy (cure time in less than 5 years);
  7. Patients with severe or poorly controlled hypertension, diabetes or cardiac dysfunction;
  8. Other comorbidities that cannot be treated with immune suppressants. In addition, once patients experience severe adverse drug reactions、ineffective treatment or rapid progression of rheumatoid arthritis, then quit this research.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03855007


Locations
Layout table for location information
China, Shandong
Qilu Hospital
Jinan, Shandong, China, 250012
Sponsors and Collaborators
Qilu Hospital of Shandong University
Investigators
Layout table for investigator information
Study Director: Ming Lv, Dr. Qilu Hospital of Shandong University
Layout table for additonal information
Responsible Party: Qiang Shu, Chief Physician, Qilu Hospital of Shandong University
ClinicalTrials.gov Identifier: NCT03855007    
Other Study ID Numbers: Iguratimod-ERA QiluH
First Posted: February 26, 2019    Key Record Dates
Last Update Posted: September 22, 2022
Last Verified: September 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Qiang Shu, Qilu Hospital of Shandong University:
Iguratimod
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Hydroxychloroquine
Prednisone
Methotrexate
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Immunosuppressive Agents
Immunologic Factors
Antirheumatic Agents